Plasmalyte Innrennslislyf, lausn आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

plasmalyte innrennslislyf, lausn

baxter medical ab* - sodium chloride; kalii chloridum; magnesii chloridum; sodium acetate trihydrate; natrii gluconas - innrennslislyf, lausn

Pedmarqsi यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - Öll önnur lækningavörur - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Phoxilium Blóðskilunar-/blóðsíunarlausn 1,2 mmol/l आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

phoxilium blóðskilunar-/blóðsíunarlausn 1,2 mmol/l

baxter holding b.v.* - calcium chloride; magnesii chloridum; sodium chloride; sodium hydrogen carbonate; kalii chloridum; disodium phosphate dodecahydrate - blóðskilunar-/blóðsíunarlausn - 1,2 mmol/l

Hemosol B0 Blóðskilunar-/blóðsíunarlausn आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

hemosol b0 blóðskilunar-/blóðsíunarlausn

baxter holding b.v.* - sodium hydrogen carbonate; sodium chloride; calcium chloride; magnesii chloridum; acidum lacticum - blóðskilunar-/blóðsíunarlausn

Movicol Junior Neutral Mixtúruduft, lausn 6,9 g आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

movicol junior neutral mixtúruduft, lausn 6,9 g

norgine healthcare b.v. - macrogol 3350; sodium hydrogen carbonate; kalii chloridum; sodium chloride - mixtúruduft, lausn - 6,9 g

Movicol Mixtúruduft, lausn 13,8 g आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

movicol mixtúruduft, lausn 13,8 g

norgine healthcare b.v. - macrogol 3350; sodium chloride; sodium hydrogen carbonate; kalii chloridum - mixtúruduft, lausn - 13,8 g

Triumeq यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

triumeq

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.